Analyst Price Targets — GSK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 30, 2025 11:27 am | Wan Nurhayati | CFRA | $53.00 | $46.67 | StreetInsider | CFRA Upgrades GlaxoSmithKline (GSK) to Buy |
| April 15, 2025 4:37 pm | Peter Verdult | BNP Paribas | $35.25 | $35.68 | TheFly | GSK initiated with a Neutral at BNP Paribas Exane |
| July 2, 2024 6:21 am | Peter Welford | Jefferies | $53.00 | $38.38 | TheFly | GSK price target raised to $53 from $52.50 at Jefferies |
| April 11, 2024 7:48 am | Vamil Divan | Guggenheim | $36.00 | $40.69 | Benzinga | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields |
| April 11, 2024 7:48 am | Mark Purcell | Morgan Stanley | $85.00 | $40.69 | Benzinga | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields |
Latest News for GSK
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure…
GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb study for irritable bowel syndrome.
GSK plc (NYSE:GSK) on Friday announced a pivotal update regarding its Phase 3 clinical program for camlipixant, revealing a strategic decision to halt further development for refractory chronic cough (RCC).
Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price target, implying roughly 30% upside from the 1,916.50p close. The broker argues a run of business development deals has brought the drugmaker's £40 billion 2031 revenue target within reach without straining the profit and loss account.
GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GSK.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.